By Matthew Stenger
Posted: 2/18/2025 11:08:00 AM
Last Updated: 2/18/2025 12:53:53 PM
Study Reveals Venetoclax/Ibrutinib Combination Improves Outcomes in Mantle Cell Lymphoma
Recent research published in The Lancet Oncology highlights a significant advancement in treating relapsed or refractory mantle cell lymphoma (MCL). Dr. Michael Wang and colleagues presented the results of the phase III SYMPATICO trial which demonstrated that venetoclax in combination with ibrutinib improved progression-free survival compared to an ibrutinib placebo.
Michael Wang, MD
Understanding the Study
The SYMPATICO trial enrolled 267 patients from across Europe, North America, and the Asia-Pacific region. Participants were randomized to receive either ibrutinib with venetoclax or single-agent ibrutinib with a placebo. The trial duration was approximately two years, with ongoing treatment with ibrutinib for patients without disease progression.
The primary objective was to assess progression-free survival in the intention-to-treat group, a standard endpoint for evaluating treatment efficacy in cancer clinical trials.
Key Study Findings
The interim analysis on overall survival found that after 24 months, patients treated with ibrutinib/venetoclax had an estimated survival rate of 66%, compared to 61% for those receiving ibrutinib alone.
According to researchers, the combined use of venetoclax and ibrutinib significantly extended progression-free survival, with a favorable safety profile consistent with individually known adverse events of both drugs.
“The combination of ibrutinib/venetoclax significantly improved progression-free survival compared with ibrutinib/placebo in patients with relapsed or refractory MCL. The safety profile was consistent with known safety profiles of the individual drugs. These findings suggest a positive benefit-risk profile for ibrutinib/venetoclax treatment.”
Financial and Disclosure Information
The research was financially supported by Pharmacyclics, a subsidiary of AbbVie, and Janssen Research and Development. Readers are advised to review full disclosure statements provided by the study authors on thelancet.com.
Implications for Patients
This study marks a significant step in advancing treatments for MCL, a subtype of non-Hodgkin’s lymphoma. The improved progression-free survival rate offers hope to patients previously resistant to ibrutinib therapy. As further analysis and real-world applications are anticipated, the combined drug therapy may redefine standards of care for this aggressive form of cancer.
Conclusion
Dr. Michael Wang’s team offers compelling evidence that venetoclax and ibrutinib, when used together, provide a promising treatment option for patients with relapsed or refractory mantle cell lymphoma. The consistency in safety and success rates suggests a potentially transformative therapy in this area of oncology.
We encourage you to share your thoughts and insights on this groundbreaking research. Join the discussion below, and subscribe for more updates on the latest in cancer treatments and research.
